Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
LaVoieHealthScience Awarded Best Pharma Product Launch at 2024 PRWeek Healthcare Awards
Menarini Presents Progression-Free Survival Data from EMERALD Clinical Study
Menarini and SciClone Pharma Announce Exclusive Sub-Licensing Collaboration
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Stemline Therapeutics` Orserdu (elacestrant) Receives Approval in Europe
FLORENCE, Italy & NEW YORK--(BUSINESS WIRE)--The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that the European Commission has approved ORSERDU® (elacestrant) as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer (mBC) with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.